{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:11:51Z","timestamp":1756991511605,"version":"3.41.0"},"reference-count":36,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T00:00:00Z","timestamp":1275955200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiol Young"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S1047951110000533_abs1\" sec-type=\"general\">\n\t    <jats:title>Objective<\/jats:title>\n\t    <jats:p>We aimed to determine whether N-terminal pro-brain natriuretic peptide can differentiate between cardiac and pulmonary aetiologies of dyspnoea, if N-terminal pro-brain natriuretic peptide can be used for evaluating the effect of treatment in cardiac failure, and for predicting severe pulmonary diseases that are complicated by cardiac failure.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S1047951110000533_abs2\" sec-type=\"methods\">\n\t    <jats:title>Methods<\/jats:title>\n\t    <jats:p>In all, 76 children with dyspnoea were enrolled; 41 of them suffered cardiac failure \u2013 25 caused by cardiac disease, 16 caused by pulmonary disease \u2013 and 35 had dyspnoea due to pulmonary disease. The control group consisted of 32 children. We calculated Ross scores, analysed N-terminal pro-brain natriuretic peptide levels, and evaluated left ventricular systolic functions by echocardiography.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S1047951110000533_abs3\" sec-type=\"results\">\n\t    <jats:title>Results<\/jats:title>\n\t    <jats:p>N-terminal pro-brain natriuretic peptide levels were significantly higher in children with cardiac failure than in those with pulmonary disease and in controls (medians 7321, 241, 87.71 picograms per millilitre, respectively), were higher in children with cardiac failure due to pulmonary disease than in those with only pulmonary disease (medians 2728, 241 picograms per millilitre, respectively), and were higher in children who died from cardiac failure than in survivors (p &lt; 0.05). After treatment of cardiac failure, N-terminal pro-brain natriuretic peptide levels decreased significantly (p &lt; 0.001). The cut-off level of N-terminal pro-brain natriuretic peptide for differentiating cardiacfailure from pulmonary disease was 726.8 picograms per millilitre, sensitivity 100%, specificity 94.3%.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S1047951110000533_abs4\" sec-type=\"conclusion\">\n\t    <jats:title>Conclusions<\/jats:title>\n\t    <jats:p>N-terminal pro-brain natriuretic peptide levels can differentiate dyspnoea due to cardiac failure from pulmonary diseases. It can also be used to monitor the effects of treatment of cardiac failure and to estimate the prognosis, as well as to predict pulmonary diseases that are complicated with cardiac failure.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/s1047951110000533","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T08:55:56Z","timestamp":1275987356000},"page":"495-504","source":"Crossref","is-referenced-by-count":9,"title":["The value of serum N-terminal pro-brain natriuretic peptide levels in the differential diagnosis and follow-up of congestive cardiac failure and respiratory distress due to pulmonary aetiologies in infants and children"],"prefix":"10.1017","volume":"20","author":[{"given":"Melike","family":"Sezgin Evim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birsen","family":"Ucar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z\u00fcbeyir","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Colak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2010,6,8]]},"reference":[{"key":"S1047951110000533_manual_ref-20","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199812000-00008"},{"key":"S1047951110000533_manual_ref-24","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.121265"},{"key":"S1047951110000533_manual_ref-1","first-page":"653","volume-title":"The Heart","author":"Francis","year":"2001"},{"key":"S1047951110000533_manual_ref-8","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.6.e76"},{"key":"S1047951110000533_manual_ref-17","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-005-1022-4"},{"key":"S1047951110000533_manual_ref-26","first-page":"279","volume-title":"The Science and Practice of Pediatric Cardiology","author":"Meliones","year":"1998"},{"key":"S1047951110000533_manual_ref-28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2003.12.013"},{"key":"S1047951110000533_manual_ref-29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2004.01.008"},{"key":"S1047951110000533_manual_ref-5","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.071233"},{"key":"S1047951110000533_manual_ref-12","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-003-0578-0"},{"key":"S1047951110000533_manual_ref-18","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-003-0461-z"},{"key":"S1047951110000533_manual_ref-30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-200X.2003.01716.x"},{"key":"S1047951110000533_manual_ref-36","doi-asserted-by":"publisher","DOI":"10.1017\/S1047951105000831"},{"key":"S1047951110000533_manual_ref-10","doi-asserted-by":"publisher","DOI":"10.1017\/S1481803500013798"},{"key":"S1047951110000533_manual_ref-22","first-page":"502","article-title":"Myokardial protective effect of puerarin injection in children with severe pneumonia","volume":"25","author":"Wang","year":"2005","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"S1047951110000533_manual_ref-13","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-1429"},{"key":"S1047951110000533_manual_ref-6","first-page":"160","article-title":"A review of the clinical utility of NT-proBNP in the diagnosis, prognosis and therapy monitoring of patients with congestive heart failure","volume":"25","author":"Ambrose","year":"2003","journal-title":"J Clin Ligand Assay"},{"key":"S1047951110000533_manual_ref-7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06031-5"},{"key":"S1047951110000533_manual_ref-11","doi-asserted-by":"publisher","DOI":"10.1097\/01.hco.0000221582.71619.84"},{"key":"S1047951110000533_manual_ref-2","doi-asserted-by":"publisher","DOI":"10.1017\/S1047951105000740"},{"key":"S1047951110000533_manual_ref-14","first-page":"1582","volume-title":"The science and practice of pediatric cardiology","author":"Dreyer","year":"1998"},{"key":"S1047951110000533_manual_ref-4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2003.12.015"},{"key":"S1047951110000533_manual_ref-34","first-page":"161","article-title":"Diagnostic value of plasma concentration of pro-brain natriuretic peptide in congestive heart failure in pediatric patients with ventricular septal defects","volume":"43","author":"Wu","year":"2005","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"S1047951110000533_manual_ref-31","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00912-8"},{"key":"S1047951110000533_manual_ref-16","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.8.875"},{"key":"S1047951110000533_manual_ref-25","first-page":"201","article-title":"Levels of serum brain natriuretic peptide in children with congestive heart failure or with severe pneumonia","volume":"8","author":"An","year":"2006","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"S1047951110000533_manual_ref-32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2003.12.012"},{"key":"S1047951110000533_manual_ref-19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi773"},{"key":"S1047951110000533_manual_ref-9","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2004.037762"},{"key":"S1047951110000533_manual_ref-21","first-page":"306","article-title":"Cardiovascular changes in children with pneumonia","volume":"45","author":"\u0130lten","year":"2003","journal-title":"Turk J Pediatr"},{"key":"S1047951110000533_manual_ref-33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2003.12.009"},{"key":"S1047951110000533_manual_ref-35","doi-asserted-by":"publisher","DOI":"10.1054\/jcaf.2001.24609"},{"key":"S1047951110000533_manual_ref-3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2004.01.004"},{"key":"S1047951110000533_manual_ref-15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cupe.2005.08.003"},{"key":"S1047951110000533_manual_ref-27","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/86.10.669"},{"key":"S1047951110000533_manual_ref-23","doi-asserted-by":"publisher","DOI":"10.1007\/BF00798207"}],"container-title":["Cardiology in the Young"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1047951110000533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T06:35:54Z","timestamp":1750487754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951110000533\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,8]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S1047951110000533"],"URL":"https:\/\/doi.org\/10.1017\/s1047951110000533","relation":{},"ISSN":["1047-9511","1467-1107"],"issn-type":[{"type":"print","value":"1047-9511"},{"type":"electronic","value":"1467-1107"}],"subject":[],"published":{"date-parts":[[2010,6,8]]}}}